临床试验中PD-1和PD-L1抑制剂治疗相关不良事件:系统综述与Meta分析
该系统综述与Meta分析纳入125项临床试验共20128例患者,评估PD-1和PD-L1抑制剂治疗相关不良事件发生率及不同药物与瘤种间的差异。任意级别不良事件发生率66.0%,≥3级为14.0%。纳武利尤单抗的全级别和≥3级不良事件发生率均高于帕博利珠单抗,但差异未达统计学显著。
要点
- 任意级别不良事件发生率66.0%,≥3级不良事件发生率14.0%。
- 最常见全级别不良事件为疲劳18.26%、瘙痒10.61%、腹泻9.47%。
- PD-1抑制剂≥3级不良事件发生率高于PD-L1抑制剂(OR 1.58,95%CI 1.00-2.54)。
核心结论
- 不同的PD-1和PD-L1抑制剂似乎具有不同的治疗相关不良事件谱。
- 临床试验中治疗相关不良事件发生率的综合总结为临床医生提供了重要指导。
研究设计与样本
- 系统综述与Meta分析,检索PubMed、Web of Science、Embase和Scopus自2017年10月1日至2018年12月15日的文献。
- 纳入已发表的单药PD-1和PD-L1抑制剂临床试验,且需有治疗相关不良事件的列表数据。
- 共纳入125项临床试验,涉及20128例患者。
- 采用贝叶斯多层回归模型进行数据分析。
主要发现
- 106项研究中的18610例患者有12277例(66.0%)发生至少1件任意级别不良事件。
- 110项研究中的18715例患者有2627例(14.0%)发生至少1件≥3级不良事件。
- 最常见的全级别不良事件为疲劳(18.26%;95%CI 16.49%-20.11%)、瘙痒(10.61%;95%CI 9.46%-11.83%)和腹泻(9.47%;95%CI 8.43%-10.58%)。
- 最常见的≥3级不良事件为疲劳(0.89%;95%CI 0.69%-1.14%)、贫血(0.78%;95%CI 0.59%-1.02%)和天冬氨酸氨基转移酶升高(0.75%;95%CI 0.56%-0.99%)。
- 最常见的全级别内分泌免疫相关不良事件为甲状腺功能减退(6.07%;95%CI 5.35%-6.85%)和甲状腺功能亢进(2.82%;95%CI 2.40%-3.29%)。
关键数值与推荐
- 纳武利尤单抗的全级别不良事件平均发生率高于帕博利珠单抗(OR 1.28;95%CI 0.97-1.79),未达统计学显著。
- 纳武利尤单抗的≥3级不良事件平均发生率高于帕博利珠单抗(OR 1.30;95%CI 0.89-2.00),未达统计学显著。
- PD-1抑制剂的≥3级不良事件平均发生率高于PD-L1抑制剂(OR 1.58;95%CI 1.00-2.54)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Programmed cell death (PD-1) and programmed cell death ligand 1 (PD-L1) inhibitors have been increasingly used in cancer therapy. Understanding the treatment-related adverse events of these drugs is critical for clinical practice. OBJECTIVE: To evaluate the incidences of treatment-related adverse events of PD-1 and PD-L1 inhibitors and the differences between different drugs and cancer types. DATA SOURCES: PubMed, Web of Science, Embase, and Scopus were searched from October 1, 2017, through December 15, 2018. STUDY SELECTION: Published clinical trials on single-agent PD-1 and PD-L1 inhibitors with tabulated data on treatment-related adverse events were included. DATA EXTRACTION AND SYNTHESIS: Trial name, phase, cancer type, PD-1 and PD-L1 inhibitor used, dose escalation, dosing schedule, number of patients, number of all adverse events, and criteria for adverse event reporting data were extracted from each included study, and bayesian multilevel regression models were applied for data analysis. MAIN OUTCOMES AND MEASURES: Incidences of treatment-related adverse events and differences between different drugs and cancer types. RESULTS: This systematic review and meta-analysis included 125 clinical trials involving 20 128 patients; 12 277 (66.0%) of 18 610 patients from 106 studies developed at least 1 adverse event of any grade (severity), and 2627 (14.0%) of 18 715 patients from 110 studies developed at least 1 adverse event of grade 3 or higher severity. The most common all-grade adverse events were fatigue (18.26%; 95% CI, 16.49%-20.11%), pruritus (10.61%; 95% CI, 9.46%-11.83%), and diarrhea (9.47%; 95% CI, 8.43%-10.58%). The most common grade 3 or higher adverse events were fatigue (0.89%; 95% CI, 0.69%-1.14%), anemia (0.78%; 95% CI, 0.59%-1.02%), and aspartate aminotransferase increase (0.75%; 95% CI, 0.56%-0.99%). Hypothyroidism (6.07%; 95% CI, 5.35%-6.85%) and hyperthyroidism (2.82%; 95% CI, 2.40%-3.29%) were the most frequent all-grade endocrine immune-related adverse events. Nivolumab was associated with higher mean incidences of all-grade adverse events compared with pembrolizumab (odds ratio [OR], 1.28; 95% CI, 0.97-1.79) and grade 3 or higher adverse events (OR, 1.30; 95% CI, 0.89-2.00). PD-1 inhibitors were associated with a higher mean incidence of grade 3 or higher adverse events compared with PD-L1 inhibitors (OR, 1.58; 95% CI, 1.00-2.54). CONCLUSIONS AND RELEVANCE: Different PD-1 and PD-L1 inhibitors appear to have varying treatment-related adverse events; a comprehensive summary of the incidences of treatment-related adverse events in clinical trials provides an important guide for clinicians.
引用
- Wang Y, Zhou S, Yang F, et al. Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-analysis. JAMA Oncol. 2019. PMID: 31021376. doi:10.1001/jamaoncol.2019.0393
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。